Comments

Ligand Pharmaceuticals

LGNDNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$101.45
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Ligand Pharmaceuticals (LGND) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$144.00
Lowest Price Target1
$90.00
Consensus Price Target1
$118.17

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Ligand Pharmaceuticals (NASDAQ:LGND) Stock, Analyst Ratings, Price Targets, Forecasts

Ligand Pharmaceuticals Inc has a consensus price target of $118.17 based on the ratings of 6 analysts. The high is $144 issued by HC Wainwright & Co. on July 8, 2024. The low is $90 issued by Roth Capital on December 23, 2022. The 3 most-recent analyst ratings were released by Craig-Hallum, HC Wainwright & Co., and Benchmark on July 9, 2024, July 8, 2024, and June 28, 2024, respectively. With an average price target of $126.33 between Craig-Hallum, HC Wainwright & Co., and Benchmark, there's an implied 24.53% upside for Ligand Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
0
0
0
0
Apr
0
0
0
0
May
0
0
0
0
Jun
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Craig-Hallum
HC Wainwright & Co.
Benchmark
Barclays
Roth Capital

1calculated from analyst ratings

Analyst Ratings for Ligand Pharmaceuticals

Buy NowGet Alert
07/09/2024Buy Now38%Craig-Hallum
Matt Hewitt
$135 → $140MaintainsBuyGet Alert
07/08/2024Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
$144 → $144ReiteratesBuy → BuyGet Alert
06/28/2024Buy Now-6.36%Benchmark
Robert Wasserman
$95 → $95ReiteratesBuy → BuyGet Alert
06/27/2024Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
$144 → $144ReiteratesBuy → BuyGet Alert
05/08/2024Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
 → $144ReiteratesBuy → BuyGet Alert
04/12/2024Buy Now-6.36%Benchmark
Robert Wasserman
 → $95ReiteratesBuy → BuyGet Alert
02/29/2024Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
 → $144ReiteratesBuy → BuyGet Alert
12/13/2023Buy Now-6.36%Benchmark
Robert Wasserman
 → $95ReiteratesBuy → BuyGet Alert
09/19/2023Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
 → $144ReiteratesBuy → BuyGet Alert
08/23/2023Buy Now-6.36%Benchmark
Robert Wasserman
 → $95ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
 → $144ReiteratesBuy → BuyGet Alert
07/25/2023Buy Now8.43%Barclays
Balaji Prasad
$120 → $110MaintainsOverweightGet Alert
06/02/2023Buy Now41.94%HC Wainwright & Co.
Joseph Pantginis
$135 → $144ReiteratesBuy → BuyGet Alert
02/21/2023Buy Now-6.36%Benchmark
Robert Wasserman
 → $95Reiterates → BuyGet Alert
12/23/2022Buy Now-11.29%Roth Capital
Scott Henry
$85 → $90MaintainsBuyGet Alert
11/21/2022Buy Now18.28%Barclays
Balaji Prasad
$150 → $120MaintainsOverweightGet Alert
10/25/2022Buy Now47.86%Barclays
Balaji Prasad
$157 → $150MaintainsOverweightGet Alert
09/02/2022Buy Now72.5%Roth Capital
Scott Henry
$185 → $175MaintainsBuyGet Alert
07/05/2022Buy Now54.76%Barclays
Balaji Prasad
$165 → $157MaintainsOverweightGet Alert
05/16/2022Buy Now28.14%Stephens & Co.
Jacob Johnson
$153 → $130MaintainsOverweightGet Alert
02/22/2022Buy Now28.14%Benchmark
Robert Wasserman
$180 → $130MaintainsBuyGet Alert
02/18/2022Buy Now62.64%Barclays
Balaji Prasad
$185 → $165MaintainsOverweightGet Alert
09/22/2021Buy Now77.43%Barclays
Balaji Prasad
—MaintainsOverweightGet Alert
07/30/2021Buy Now87.28%Roth Capital
Scott Henry
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for Ligand Pharmaceuticals (LGND) stock?

A

The latest price target for Ligand Pharmaceuticals (NASDAQ:LGND) was reported by Craig-Hallum on July 9, 2024. The analyst firm set a price target for $140.00 expecting LGND to rise to within 12 months (a possible 38.00% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?

A

The latest analyst rating for Ligand Pharmaceuticals (NASDAQ:LGND) was provided by Craig-Hallum, and Ligand Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for Ligand Pharmaceuticals (LGND)?

A

There is no last upgrade for Ligand Pharmaceuticals

Q

When was the last downgrade for Ligand Pharmaceuticals (LGND)?

A

There is no last downgrade for Ligand Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.

Q

Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?

A

While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a maintained with a price target of $135.00 to $140.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $101.45, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch